Varubi is called Varuby in Europe.
Information about Varubi (Rolapitant)
Varubi (Rolapitant) is a medication used to prevent nausea and vomiting associated with chemotherapy. It is specifically designed to address delayed nausea, which can occur after chemotherapy treatment. Varubi belongs to a class of drugs known as neurokinin-1 (NK1) receptor antagonists, which work by blocking a substance in the brain that causes nausea and vomiting.
Product Highlights
- Prevention of delayed nausea and vomiting caused by highly or moderately emetogenic chemotherapy.
- It is typically administered as part of a comprehensive regimen aimed at preventing chemotherapy-induced nausea and vomiting (CINV), specifically targeting the delayed phase (24 hours or more after chemotherapy).
Key Ingredient
Key Benefits
- It significantly reduces the risk of delayed nausea and vomiting, which can last up to 5 days after chemotherapy.
- Its prolonged action means that a single dose can be effective for several days.
- Rolapitant has a favorable side effect profile, with fewer central nervous system side effects like sedation compared to some other antiemetics.
Direction of Use
- Varubi is usually administered as an intravenous (IV) infusion or as an oral tablet.
- The typical dose of Varubi is a single dose taken 1-2 hours before the start of chemotherapy. For IV use, it is typically administered on the day of chemotherapy.
- It may be used in combination with other medications like a corticosteroid and 5-HT3 receptor antagonists, depending on the chemotherapy regimen.
Safety Concerns
- Varubi may interact with certain medications, particularly those metabolized by the liver (CYP3A4 enzymes), as it may alter their effects.
- Caution is advised for patients with hepatic (liver) impairment, as the drug may be processed more slowly in such individuals.
- Some common side effects include headache, fatigue, and gastrointestinal issues like constipation.
Avoid Varubi (Rolapitant) If
- If you have a known allergy or hypersensitivity to rolapitant or any of the ingredients in Varubi.
- Individuals with severe liver impairment may be at risk for increased side effects due to slower drug clearance.
- Varubi should only be used during pregnancy if the potential benefit justifies the risk to the fetus, as safety in pregnancy has not been established.
- If you're taking drugs that significantly alter the activity of CYP3A4 enzymes (such as certain antifungals, HIV protease inhibitors, or some antibiotics), Varubi may not be appropriate without careful monitoring.
